Table 3.
The effects of antidepressant drugs on Arc expression in rodents.
| Species/Strain | Sex | Drug | Dose (mg/kg) | Route | Timing | Action | Arc | Brain Regions | References |
|---|---|---|---|---|---|---|---|---|---|
| Rat/SD | M | Fluoxetine | 10 | i.p. | Acute | 5-HTT inhibitor | – | – | Alme et al., 2007 |
| Rat/SD | M | Paroxetine | 5 | s.c. | Acute | 5-HTT inhibitor | – | – | Castro et al., 2003 |
| Rat/SD | M | Paroxetine | 5 | i.p. | Acute | 5-HTT inhibitor | – | – | Tordera et al., 2003 |
| Rat/SD | M | Paroxetine | 5 | i.p. | Acute | 5-HTT inhibitor | – | – | Pei et al., 2003 |
| Rat/SD | M | Desipramine | 5 | i.p. | Acute | NET inhibitor | – | – | Pei et al., 2003 |
| Rat/SD | M | Venlafaxine | 5 | i.p. | Acute | 5-HTT, NET inhibitor | – | – | Pei et al., 2003 |
| Rat/SD | M | Venlafaxine | 10 | i.p. | Acute | 5-HTT, NET inhibitor | – | – | Serres et al., 2012 |
| Rat/SD | M | Duloxetine | 10 | p.o. | Acute | 5-HTT, NET inhibitor | Decreased | FC | Molteni et al., 2008 |
| Rat/SD | M | Duloxetine | 10 | p.o. | Acute | 5-HTT, NET inhibitor | Increased | EC, MB | Molteni et al., 2008 |
| Rat/SD | M | Fluoxetine | 10 | p.o. | 4 days | 5-HTT inhibitor | – | – | De Foubert et al., 2004 |
| Mouse/C57BL/6J | M | Fluoxetine | 20 | i.p. | 4 days | 5-HTT inhibitor | – | – | Ferrés-Coy et al., 2013 |
| Rat/SD | M | Fluoxetine | 10 | p.o. | 1 week | 5-HTT inhibitor | – | – | De Foubert et al., 2004 |
| Rat/SD | M | Venlafaxine | 10 | i.p. | 1 week | 5-HTT, NET inhibitor | – | – | Serres et al., 2012 |
| Rat/SD | M | Fluoxetine | 10 | p.o. | 2 weeks | 5-HTT inhibitor | Increased | CC, OFC | De Foubert et al., 2004 |
| Mouse/C57BL/6J | M | Fluoxetine | 20 | i.p. | 2 weeks | 5-HTT inhibitor | Increased | DG | Ferrés-Coy et al., 2013 |
| Rat/SD | M | Paroxetine | 5; b.i.d. | i.p. | 2 weeks | 5-HTT inhibitor | Increased | FC, OFC, PC, CA1 | Pei et al., 2003 |
| Rat/SD | M | Desipramine | 5; b.i.d. | i.p. | 2 weeks | NET inhibitor | Increased | FC, CC, OFC, PC, CA1 | Pei et al., 2003 |
| Rat/SD | M | Venlafaxine | 5; b.i.d. | i.p. | 2 weeks | 5-HTT, NET inhibitor | Increased | PC, CA1 | Pei et al., 2003 |
| Rat/SD | M | Venlafaxine | 10 | i.p. | 2 weeks | 5-HTT, NET inhibitor | Increased | CC, PC | Serres et al., 2012 |
| Rat/SD | M | Fluoxetine | 10 | i.p. | 3 weeks | 5-HTT inhibitor | Increased | HC | Alme et al., 2007 |
| Rat/FSL | M | Escitalopram | 330 mg drug/kg food | p.o. | 3 weeks | 5-HTT inhibitor | Increased | CA1, DG | Eriksson et al., 2012 |
| Rat/FSL | M | Nortriptyline | 330 mg drug/kg food | p.o. | 3 weeks | 5-HTT, NET inhibitor | – | – | Eriksson et al., 2012 |
| Rat/SD | M | Duloxetine | 10 | p.o. | 3 weeks | 5-HTT, NET inhibitor | Increased | FC, EC, MB | Molteni et al., 2008 |
| Rat/SD | NR | Venlafaxine | 10 | i.p. | 3 weeks | 5-HTT, NET inhibitor | Increased | HC | Calabrese et al., 2011 |
| Rat/SD | NR | Venlafaxine | 10 | i.p. | 3 weeks | 5-HTT, NET inhibitor | Decreased | FC | Calabrese et al., 2011 |
| Rat/SD | NR | Agomelatine | 40 | i.p. | 3 weeks | Melatonin1receptor agonist, melatonin2 receptor agonist, 5-HT2C receptor antagonist | Increased | HC | Calabrese et al., 2011 |
| Rat/Wistar | M | Imipramine | 20 | p.o. | 7 weeks | 5-HTT, NET inhibitor | Increased | FC, DG | Wibrand et al., 2013 |
| Rat/Wistar | F | Imipramine | 20 | p.o. | 7 weeks | 5-HTT, NET inhibitor | Increased | DG | Wibrand et al., 2013 |
5-HTT, 5-HT transporter; b.i.d., bis in die; CA1, cornu ammonis area 1; CC, cingulate cortex; DG, dentate gyrus; EC, entorhinal cortex; F, female; FC, frontal cortex; FSL, Flinders Sensitive Line; HC, hippocampus; M, male; MB, midbrain; NET, norepinephrine transporter; NR, not reported; OFC, orbitofrontal cortex; PC, parietal cortex; SD, Sprague Dawley.